Total Payments
$198,461
2024 Payments
$13,504
Companies
19
Transactions
488
Medicare Patients
1,144
Medicare Billing
$200,666
Payment Breakdown by Category
Other$164,748 (83.0%)
Travel$18,010 (9.1%)
Food & Beverage$10,848 (5.5%)
Consulting$4,600 (2.3%)
Education$255.02 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $164,748 | 79 | 83.0% |
| Travel and Lodging | $18,010 | 76 | 9.1% |
| Food and Beverage | $10,848 | 324 | 5.5% |
| Consulting Fee | $4,600 | 1 | 2.3% |
| Education | $255.02 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $148,367 | 227 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $38,055 | 89 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $9,738 | 16 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $633.83 | 65 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $480.47 | 38 | $0 (2022) |
| Allergan, Inc. | $245.30 | 18 | $0 (2020) |
| Neurocrine Biosciences, Inc. | $202.57 | 6 | $0 (2022) |
| ABBVIE INC. | $143.75 | 7 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $133.44 | 7 | $0 (2020) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $122.95 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,504 | 39 | Alkermes, Inc. ($9,514) |
| 2023 | $29,731 | 29 | Alkermes, Inc. ($23,581) |
| 2022 | $18,966 | 48 | Alkermes, Inc. ($18,833) |
| 2021 | $27,962 | 35 | Alkermes, Inc. ($27,674) |
| 2020 | $25,525 | 75 | Alkermes, Inc. ($23,489) |
| 2019 | $41,559 | 117 | Alkermes, Inc. ($33,123) |
| 2018 | $23,687 | 87 | Alkermes, Inc. ($11,997) |
| 2017 | $17,528 | 58 | Otsuka America Pharmaceutical, Inc. ($17,121) |
All Payment Transactions
488 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $15.37 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/04/2024 | Janssen Pharmaceuticals, Inc | INVEGA (Drug) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: Neuroscience | ||||||
| 11/07/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: CNS | ||||||
| 10/30/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $36.24 | General |
| Category: CNS | ||||||
| 10/24/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Central Nervous System | ||||||
| 10/23/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $98.91 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/25/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: PSYCHIATRY | ||||||
| 09/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $91.45 | General |
| Category: PSYCHIATRY | ||||||
| 08/07/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: CNS | ||||||
| 08/02/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: PSYCHIATRY | ||||||
| 07/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,430.00 | General |
| Category: CNS | ||||||
| 07/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: CNS | ||||||
| 07/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: CNS | ||||||
| 07/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $36.00 | General |
| Category: CNS | ||||||
| 06/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $606.20 | General |
| Category: CNS | ||||||
| 06/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: CNS | ||||||
| 06/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $69.46 | General |
| Category: CNS | ||||||
| 06/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $46.34 | General |
| Category: CNS | ||||||
| 06/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $29.50 | General |
| Category: CNS | ||||||
| 06/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: CNS | ||||||
| 06/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: CNS | ||||||
| 06/08/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: CNS | ||||||
| 06/07/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $121.20 | General |
| Category: CNS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 238 | 829 | $103,835 | $43,002 |
| 2022 | 8 | 350 | 1,245 | $152,618 | $67,120 |
| 2021 | 6 | 314 | 1,150 | $148,851 | $62,090 |
| 2020 | 5 | 242 | 570 | $63,438 | $28,454 |
Total Patients
1,144
Total Services
3,794
Medicare Billing
$200,666
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 376 | $53,016 | $22,081 | 41.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 28 | 230 | $17,480 | $8,396 | 48.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 60 | 85 | $12,070 | $4,817 | 39.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 36 | 45 | $12,105 | $3,504 | 28.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 24 | 48 | $3,665 | $2,338 | 63.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 28 | $2,134 | $972.66 | 45.6% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 13 | 17 | $3,366 | $894.01 | 26.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 57 | 599 | $84,459 | $32,443 | 38.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 60 | 222 | $16,916 | $11,396 | 67.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 45 | 64 | $17,216 | $6,365 | 37.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 52 | 115 | $8,763 | $5,469 | 62.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 52 | 89 | $12,638 | $4,858 | 38.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 11 | 76 | $5,776 | $2,238 | 38.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 30 | 30 | $2,538 | $1,928 | 75.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 20 | 20 | $1,692 | $1,131 | 66.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 11 | $1,468 | $761.01 | 51.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 12 | 19 | $1,151 | $530.95 | 46.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 73 | 712 | $100,392 | $39,187 | 39.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 78 | 165 | $12,573 | $8,340 | 66.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 60 | 83 | $11,786 | $4,671 | 39.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 39 | 48 | $12,912 | $4,415 | 34.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 18 | 96 | $7,296 | $2,879 | 39.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 46 | 46 | $3,892 | $2,598 | 66.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 104 | 282 | $21,488 | $10,986 | 51.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 49 | 194 | $27,354 | $10,931 | 40.0% |
About Dr. Omar Colon, M.D
Dr. Omar Colon, M.D is a Psychiatry healthcare provider based in Oswego, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2012. The National Provider Identifier (NPI) number assigned to this provider is 1093061293.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Omar Colon, M.D has received a total of $198,461 in payments from pharmaceutical and medical device companies, with $13,504 received in 2024. These payments were reported across 488 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($164,748).
As a Medicare-enrolled provider, Colon has provided services to 1,144 Medicare beneficiaries, totaling 3,794 services with total Medicare billing of $200,666. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Oswego, NY
- Active Since 07/25/2012
- Last Updated 02/07/2024
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1093061293
Products in Payments
- ARISTADA (Drug) $99,815
- ABILIFY MAINTENA (Drug) $37,632
- LYBALVI (Drug) $36,377
- Aristada 441 mg (Drug) $12,152
- UZEDY (Drug) $9,450
- LATUDA (Drug) $480.47
- INVEGA SUSTENNA (Drug) $457.87
- REXULTI (Drug) $422.90
- VRAYLAR (Drug) $389.05
- INGREZZA (Drug) $202.57
- CAPLYTA (Drug) $122.95
- Auvelity (Drug) $114.28
- Fanapt (Drug) $83.15
- PERSERIS (Drug) $77.80
- SPRAVATO (Drug) $76.96
- NEUROSTAR TMS THERAPY (Device) $61.38
- INVEGA (Drug) $54.62
- HETLIOZ (Drug) $50.29
- AUSTEDO (Drug) $44.29
- Austedo XR (Drug) $36.53
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.